Did you know that up to 30% of Lassa fever survivors develop sensorineural hearing loss (SNHL)? This often-permanent condition not only affects quality of life but also raises important questions about vaccine safety. In our latest blog post, we explore insights from the recent SPEAC webinar, where global experts, including INSIS Co-lead Dr. Karina Top and PI Investigator Dr. Steven Black, discussed the immune mechanisms behind LASV-associated SNHL and the measures needed to ensure the safety of Lassa virus vaccines.

Discover how innovative technologies, multi-OMICs approaches, and robust clinical trial methodologies are paving the way for safer, more effective vaccines.